Structure for real-time nicotine-detecting biosensor, biosensor comprising same, and method for analyzing nicotine in saliva in real time by using biosensor
The real-time nicotine detection biosensor uses a crystalline carbon film and TRPA1-containing nanovesicles to measure calcium ion changes, addressing the challenge of real-time nicotine analysis in saliva with high sensitivity and convenience, effectively determining smoking status with a 1 pM detection limit.
Patent Information
- Application Number
- PCT/KR2024/005191
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2024-04-18
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods for detecting nicotine in saliva are not suitable for real-time analysis, and existing techniques, such as cotinine detection, face challenges like human rights issues and inconvenience, especially when trying to determine smoking status accurately and reliably.
A real-time nicotine detection biosensor structure comprising a crystalline carbon film, a calcium ion selective film, and nanovesicles containing TRPA1, which quantitatively measures nicotine concentration by detecting changes in calcium ion flow, allowing for precise nicotine detection even at low concentrations.
The biosensor enables real-time, quantitative analysis of nicotine in saliva with a detection limit of 1 pM, providing a reliable and convenient method for determining smoking status, suitable for public health applications.
Smart Images

Figure KR2024005191_14112024_PF_FP_ABST
Abstract
Description
Structure for real-time nicotine detection biosensor, biosensor including same, and real-time nicotine analysis method in saliva using biosensor
[0001] The present invention relates to a biosensor, and more particularly, to an electrochemical biosensor.
[0002] Reports of various diseases caused by smoking are continually being published. Specifically, numerous epidemiological studies have demonstrated that inhaled tobacco smoke is a major environmental carcinogen. For example, the incidence of lung cancer has been reported to be more than ten times higher in male smokers than in non-smokers.
[0003] Currently, 30-40% of cancers occurring in the population are caused by tobacco use (including cancers of the lungs, oral cavity, esophagus, kidneys, bladder, and pancreas). Specifically, 83% of lung cancers are attributed to smoking. Other diseases known to be linked to smoking include heart disease, particularly coronary artery disease, respiratory diseases like chronic bronchitis, various pregnancy complications, and peptic ulcers.
[0004] Meanwhile, secondhand smoke is when people around a smoker indirectly inhale cigarette smoke regardless of their will, even if they are not smoking directly. At this time, the toxic chemicals in the sidestream smoke, which is the smoke from the end of the cigarette, can cause serious harm to secondhand smokers.
[0005] The harmful effects of smoking are more severe in adolescents because their bodies are not fully developed yet and all their cells and tissues are weak.
[0006] Therefore, accurately assessing smoking status is crucial in research and patient care related to smoking and smoking cessation. There are various methods for assessing smoking status. Among these, self-reporting through questionnaires has low reliability, and it is crucial to assess smoking status through testing for specific substances.
[0007] Smoking status can be measured by detecting components or metabolites of tobacco smoke in bodily fluids such as urine, blood, saliva, sweat, or hair. Among these, nicotine, a substance specific to tobacco, is theoretically the most desirable indicator for assessing smoking status. However, nicotine has a short half-life of approximately two hours, making it difficult to accurately detect because it is converted to metabolites after two hours.
[0008] Previously, methods for detecting cotinine, a nicotine metabolite, were utilized. However, measuring cotinine in urine not only entails the inconvenience of having to use the restroom, but also raises human rights concerns and raises the risk of subjects altering or tampering with the sample. Consequently, methods for detecting cotinine in saliva have been proposed, but this method suffers from the problem of not being able to measure in real time.
[0009] Accordingly, there is a need for a technology that can determine smoking status simply and in real time through saliva.
[0010] The problem to be solved by the present invention is to provide a biosensor capable of quantitatively analyzing nicotine concentration in simple and real time through saliva.
[0011] To solve the above problem, one aspect of the present invention provides a structure for a real-time nicotine detection biosensor. The structure comprises a crystalline carbon film; a calcium ion-selective film formed on the crystalline carbon film; and a nanovesicle comprising TRPA1 (Transient receptor potential channel, subfamily A, member 1) formed on the calcium ion-selective film.
[0012] The nanovesicles containing the above TRPA1 can be immobilized on the calcium ion selective membrane by chemical bonding.
[0013] The above chemical bond can be fixed using poly-D-lysine as a linker.
[0014] In addition, another aspect of the present invention provides a real-time nicotine detection biosensor comprising the structure.
[0015] The above real-time nicotine detection biosensor is characterized by quantitatively detecting the nicotine concentration in saliva.
[0016] The above real-time nicotine detection biosensor can quantitatively detect nicotine concentration by detecting changes in the concentration of calcium ions that occur when nicotine in saliva selectively reacts with TRPA1 on a structure within the sensor and calcium ions in saliva flow into nanovesicles containing TRPA1.
[0017] The above real-time nicotine detection biosensor may have a detection limit of nicotine of 1 pM.
[0018] Furthermore, another aspect of the present invention provides a method for analyzing nicotine in saliva in real time using the biosensor. The method comprises the steps of: processing a saliva sample to be measured into the biosensor; and measuring an electrical signal from the biosensor.
[0019] The measurement of the above electrical signal may be a measurement of a change in open circuit voltage (OCV).
[0020] The above analysis method may further include a step of quantitatively analyzing the nicotine concentration according to the magnitude of change in the electrical signal of the biosensor.
[0021] The above analysis method is characterized in that the detection limit of nicotine is 1 pM.
[0022] According to the present invention, since the structure connected to the electrode of the biosensor forms a structure of a crystalline carbon film / calcium ion-selective membrane / TRPA1-containing nanovesicle, when nicotine is contained in saliva containing calcium ions, the nanovesicle having the TRPA1 ion channel in the outermost layer of the structure specifically reacts to the nicotine contained in the saliva and introduces calcium ions, and the change in the calcium ion concentration caused thereby changes the surface potential of the crystalline carbon film in contact with the calcium ion-selective membrane through the calcium ion-selective membrane. Accordingly, the electrical conductivity changes, and the change in the electrical conductivity, for example, the change in the open-circuit voltage, can be measured to quantitatively analyze the concentration of nicotine. In particular, since the biosensor including the structure according to the present invention can detect nicotine even in an extremely trace amount of 1 pM, the concentration of nicotine in the saliva of a smoker can be quantitatively determined in real time. In addition, the biosensor including the structure according to the present invention is economical because the material is easy to obtain, the manufacturing method is simple, and mass production is possible, so it can be quickly applied in actual fields such as public health centers.
[0023] Figure 1 is a schematic diagram of a structure for a real-time nicotine detection biosensor according to one embodiment of the present invention.
[0024] Figure 2 shows a method for manufacturing a structure for a real-time nicotine detection biosensor according to one embodiment of the present invention.
[0025] FIG. 3 is a schematic diagram showing the operating principle when a smoker's actual saliva is introduced into a biosensor including a nanovesicle structure including CNT / ISM / TRPA1 according to one embodiment of the present invention.
[0026] FIG. 4 shows energy dispersive X-ray spectroscopy (EDX) spectra and field emission-scanning electron microscopy (FE-SEM) images of a CNT film and a CNT / ISM film according to a comparative example and an embodiment of the present invention.
[0027] FIG. 5 is a graph showing the change in open circuit voltage (OCV) over time when an electrode having a CNT film and a CNT / ISM film attached thereto according to a comparative example and an embodiment of the present invention is positioned in artificial saliva containing calcium ions and exposed to a 1% concentration of tobacco smoke extract.
[0028] FIG. 6 is a graph showing the change in open circuit voltage (OCV) when an electrode having a CNT film and a CNT / ISM film attached thereto according to a comparative example and an embodiment of the present invention is placed in artificial saliva containing calcium ions, and 2 mM MgCl2, 2 mM KCl, 2 mM NaCl, and 2 mM CaCl2 are added to the artificial saliva.
[0029] Figure 7 is a graph showing the change in fluorescence intensity of cells over time when a calcium ion-sensitive fluorescent dye was added to HEK-293T cells mock-infected with TRPA1 or an empty vector and a cigarette smoke extract (CSE) solution was applied.
[0030] Figure 8 is a graph showing the change in fluorescence intensity of nanovesicles over time when a calcium ion-sensitive fluorescent dye is added to nanovesicles containing TRPA1 or nanovesicles isolated from HEK-293T cells mock-infected with an empty vector, and a cigarette smoke extract (CSE) solution is applied.
[0031] FIG. 9 is a graph showing the detection performance of a biosensor including a nanovesicle structure including CNT / ISM / TRPA1 according to one embodiment of the present invention according to nicotine concentration.
[0032] FIG. 10 is a graph showing the detection performance of a biosensor including a nanovesicle structure including CNT / ISM / TRPA1 according to one embodiment of the present invention according to the concentration of nicotine in actual saliva.
[0033] Hereinafter, embodiments of the present invention will be described in detail with reference to the attached drawings. In describing the present invention, detailed descriptions of related known functions or configurations will be omitted if they are deemed to unnecessarily obscure the gist of the present invention. Furthermore, the terms used in this specification are terms intended to appropriately express preferred embodiments of the present invention and may vary depending on the intentions of the user or operator, or customary practices in the field to which the present invention pertains. Therefore, definitions of these terms should be based on the contents throughout this specification.
[0034] Identical reference numerals in each drawing represent identical elements.
[0035] Throughout the specification, when we say that an element is "on" another element, this includes not only cases where the element is in contact with the other element, but also cases where another element exists between the two elements.
[0036] Throughout the specification, whenever a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise stated.
[0037]
[0038] [Structure for a real-time nicotine detection biosensor]
[0039] One aspect of the present invention provides a structure for a real-time nicotine detection biosensor.
[0040] Figure 1 is a schematic diagram of a structure for a real-time nicotine detection biosensor according to one embodiment of the present invention.
[0041] Referring to FIG. 1, a structure for a real-time nicotine detection biosensor according to the present invention is characterized by including a crystalline carbon film (10), a calcium ion selective membrane (ISM) (20) formed on the crystalline carbon film, and a nanovesicle (40) including TRPA1 (Transient receptor potential channel, subfamily A, member 1) formed on the calcium ion selective membrane.
[0042] The above crystalline carbon film (10) has high strength, chemical or biological inertness with surrounding cells, and excellent electrical conductivity, so that when reacting with biomolecules in a biosensor, high-sensitivity signal conversion is possible through changes in the surface potential of the crystalline carbon film. A carbon material with high electrical conductivity, such as carbon nanotubes (CNTs) or graphene, can be used as the crystalline carbon film.
[0043] The calcium ion selective membrane (20) is positioned on the crystalline carbon membrane (10), and uses a polymer as a matrix that maintains the shape of the membrane, and includes an ion-selective substance (ionophore) that causes charge separation by binding to a specific ion, i.e., calcium ion, a plasticizer that is a non-volatile organic solvent, and a lipophilic additive. The calcium ion selective membrane (20) acts as a physical barrier that blocks the interference of various ion species contained in cigarette smoke in the saliva of a smoker by the lipophilic additive, and at the same time, acts to transfer a specific ion, i.e., calcium ion, to the crystalline carbon membrane through the ionophore.
[0044] The above calcium ion selective membrane (20) was selected in consideration of the fact that the TRPA1 ion channel in the nanovesicle containing TRPA1 (hereinafter, 'TRPA1-containing nanovesicle') described below reacts with nicotine in cigarette smoke to introduce calcium ions, thereby causing a change in calcium ions, and through this, the reaction and concentration of nicotine can be detected by measuring the change in calcium ion concentration.
[0045] On the calcium ion selective membrane (20) above, nanovesicles (40) containing TRPA1 are formed.
[0046] In the present invention, the term 'nanovesicle' refers to a nanometer-sized vesicle surrounded by a membrane composed of a phospholipid bilayer, and may be used interchangeably with 'nanoesophagus' or 'nanavesicle'. Nanovesicles may have the same or similar size and structure as exosomes, which are membrane-structured vesicles secreted from various types of cells. However, unlike exosomes, which are released outside of cells and bind to other cells and tissues to deliver substances such as proteins and RNA within the vesicles, nanovesicles are artificially obtained from cells. The nanovesicles have the form of vesicles surrounded by a membrane composed of a lipid bilayer, and there may be one or more lipid bilayer membranes.
[0047] The above nanovesicles contain TRPA1. The TRPA1 may be located on the membrane surface of the nanovesicles, and other proteins, glycoproteins, cholesterol, etc. may be bound to the membrane surface in addition to TRPA1. The nanovesicles have a cell-like structure, and thus can provide an environment similar to an actual intracellular environment or cell membrane. Therefore, since TRPA1, which is originally present on the cell membrane surface in vivo, is included in the nanovesicles, there is an advantage in that it can function identically or similarly to how TRPA1 functions in vivo.
[0048] The above TRPA1 is a type of ion channel protein, also called 'transient receptor potential ankyrin 1', located on the surface of the biological membrane of animal cells including humans, and is a receptor related to somatic sensations such as pain, cold, and itching, detecting physical and chemical stress. When the TRPA1 selectively binds to the nicotine, its structure changes and the channel opens, allowing ions existing outside the nanovesicle, such as calcium ions, to move into the inside of the nanovesicle. Accordingly, the TRPA1 can be used to confirm the presence of nicotine by measuring the change in calcium ion concentration.
[0049] The TRPA1 of the present invention can be obtained using various methods widely known in the art. For example, it can be produced using polynucleotide recombination and protein expression systems, in vitro synthesis through chemical synthesis such as peptide synthesis, and cell-free protein synthesis methods.
[0050] In addition, a protecting group may be bonded to the N-terminus or C-terminus of the protein to obtain better chemical stability, enhanced pharmacological properties (half-life, absorbability, potency, efficacy, etc.), altered specificity (e.g., broad biological activity spectrum), and reduced antigenicity. For example, the protecting group may be an acetyl group, a fluorenyl methoxy carbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or polyethylene glycol (PEG), but any component that can modify the protein, particularly enhance the stability of the protein, may be included without limitation. The 'stability' refers not only to stability in vivo, which protects the protein of the present invention from attack by in vivo protein cleavage enzymes, but also to storage stability (e.g., room temperature storage stability).
[0051] The nanovesicles containing the TRPA1 may be manufactured by producing and isolating them from animal cells. Specifically, TRPA1 may be expressed from animal cells transformed with a gene encoding the TRPA1 protein, and the animal cells may be treated with a substance that reduces the stability of the cell membrane, such as cytochalasin B, and then centrifuged to obtain nanovesicles. Transforming the TRPA1 protein-encoding gene may utilize any technology and method known in the art of the present invention to transform a specific gene into an animal cell. For example, the TRPA1-encoding gene may be cloned into an expression vector and transformed into an animal cell through treatment with a lipofectamine solution.
[0052] The diameter of the nanovesicle containing the above TRPA1 may be 100 nm to 200 nm, specifically, 120 nm to 200 nm, 140 nm to 180 nm, 120 nm to 180 nm, or 140 nm to 160 nm. When the diameter of the nanovesicle is within the above range, the nanovesicle can be effectively immobilized on a calcium ion-selective membrane.
[0053] The nanovesicles containing the TRPA1 may be chemically bonded to the calcium ion-selective membrane. The immobilization means that the nanovesicles containing the TRPA1 are fixed at a position on the calcium ion-selective membrane so that they do not move.
[0054] The above chemical bond may be immobilized using any one selected from the group consisting of poly-D-lysine (or PDL), poly-L-lysine, and poly-L-ornithine as a linker (30), but is not limited thereto, and any form may be used as long as it has the property of allowing electron carriers (electrons or holes) to move therethrough and binding to each of the calcium ion selective membrane (20) and the nanovesicles (40) containing TRPA1. The poly-D-lysine is a polymer in which multiple D-lysines are linked, and can form an ionic bond and bind to the surfaces of the calcium ion selective membrane and the nanovesicles by utilizing the cation properties exhibited by lysine. Therefore, the surface of the calcium ion-selective membrane can be modified by coating the calcium ion-selective membrane with poly-di-lysine, and the TRPA1-containing nanovesicles can be immobilized on the calcium ion-selective membrane by binding the TRPA1-containing nanovesicles to the poly-di-lysine.
[0055]
[0056] Figure 2 shows a method for manufacturing a structure for a real-time nicotine detection biosensor according to one embodiment of the present invention.
[0057] Referring to FIG. 2, the method for manufacturing a structure for a real-time nicotine detection biosensor according to the present invention is as follows:
[0058] Step of forming a crystalline carbon film;
[0059] A step of forming a calcium ion selective film on the above crystalline carbon film;
[0060] a step of fixing a linker on the calcium ion selective membrane; and
[0061] A step of fixing a nanovesicle containing TRPA1 to the above linker is included.
[0062]
[0063] The above crystalline carbon film can be formed on a substrate or electrode commonly used in biosensors in the art.
[0064] The substrate may be a rigid substrate or a flexible substrate. For example, the substrate may be a rigid substrate such as an insulating inorganic substrate such as a Si substrate, a glass substrate, a GaN substrate, a silica (SiO2) substrate, a metal substrate such as Ni, Cu, W, or a plastic substrate, or a flexible substrate that can be folded or bent such as at least one of polyimide (PI), polypropylene (PP), polyester (PET), polyethylene (PE), polyvinyl chloride (PVC), polyamide (PA), oriented polypropylene (OPP), ethylene vinyl acetate copolymer (EVA), polyurethane (PU), polydimethylsiloxane (PDMS), silicone, or latex, but is not limited thereto.
[0065] The electrode may be electrically connected and may include a conductive material, and may be formed of, for example, a metal, a metal alloy, a conductive metal oxide, a conductive metal nitride, a carbon electrode, or the like.
[0066] The formation of the above crystalline carbon film and calcium ion selective film can be performed using a solution process or a deposition process.
[0067] The above solution process may include spin-coating, drop-casting, bar coating, slot-die coating, gravure printing, nozzle printing, inkjet printing, screen printing, electrohydrodynamic jet printing, electrospray, etc.
[0068] The above deposition process may include evaporation, thermal deposition, flash deposition, laser deposition, chemical vapor deposition, atomic layer deposition, physical vapor deposition, physical-chemical coevaporation deposition, sequential vapor deposition, solution process-assisted thermal deposition, etc.
[0069] The above linker may be selected from the group consisting of poly-D-lysine (or PDL), poly-L-lysine, and poly-L-ornithine, but is not limited thereto, and may be used in any form as long as it has the property of being able to bind to each of the calcium ion selective membrane (20) and the nanovesicle (40) containing TRPA1 while allowing electron carriers (electrons or holes) to move therethrough.
[0070] For example, the surface of the calcium ion-selective membrane can be modified by coating the calcium ion-selective membrane with poly-di-lysine, and the TRPA1-containing nanovesicles can be immobilized on the calcium ion-selective membrane by binding the TRPA1-containing nanovesicles to the poly-di-lysine.
[0071]
[0072] Real-time nicotine detection biosensor
[0073] In addition, another aspect of the present invention provides a real-time nicotine detection biosensor comprising the structure.
[0074] In one embodiment of the present invention, the biosensor is characterized in that the structure is formed on an electrode or the structure is formed so as to be connected to an electrode.
[0075] The biosensor may be a two-electrode type biosensor composed of a working electrode and a counter electrode, or a three-electrode type biosensor composed of a working electrode, a counter electrode, and a reference electrode. In one embodiment of the present invention, the biosensor uses a three-electrode type biosensor composed of a working electrode (1), a counter electrode (2), and a reference electrode (3), as shown in Fig. 2, but is not limited thereto. In addition, the biosensor may be a transistor type biosensor.
[0076]
[0077] FIG. 3 is a schematic diagram showing the operating principle when a smoker's actual saliva is introduced into a biosensor including a structure according to one embodiment of the present invention.
[0078] Referring to FIG. 3, since the structure connected to the electrode of the biosensor according to the present invention forms a structure of a crystalline carbon film / calcium ion selective membrane / TRPA1-containing nanovesicle, when actual saliva of a smoker is introduced into the biosensor, if nicotine is contained in the saliva containing calcium ions, the nanovesicle having the TRPA1 ion channel in the outermost layer of the structure connected to the electrode of the biosensor does not react with other components in the saliva, but reacts specifically to the nicotine contained in the saliva to introduce calcium ions, and the change in the calcium ion concentration caused thereby changes the surface potential of the crystalline carbon film in contact with the calcium ion selective membrane through the calcium ion selective membrane, thereby detecting a change in electrical conductivity, for example, a change in open circuit voltage, so that the nicotine concentration can be quantitatively detected in real time.
[0079] The above biosensor has a detection limit of nicotine of 1 pM, making it useful for detecting low concentrations of nicotine present in saliva. Since it can detect in real time, it can be quickly applied in actual fields such as public health centers.
[0080]
[0081] Real-time nicotine analysis method in saliva
[0082] In addition, another aspect of the present invention provides a method for analyzing nicotine in saliva in real time using the biosensor.
[0083] The method includes a step of processing a saliva sample of a measurement target into the real-time nicotine detection biosensor; and a step of measuring an electrical signal of the real-time nicotine detection biosensor.
[0084] The above detection means confirming the presence of a target substance and includes quantitatively or semi-quantitatively determining the concentration of the target substance, nicotine.
[0085] The measurement subjects may include smokers or non-smokers, and may be specifically targeted at smokers.
[0086] The measurement of the above electrical signal may be a measurement of a change in open circuit voltage (OCV), and by measuring the change in OCV, the presence or absence of nicotine in the saliva sample and / or the concentration or amount of nicotine can be detected.
[0087] The method for analyzing nicotine in real time in saliva using the above biosensor may further include a step of quantitatively analyzing the nicotine concentration according to the magnitude of change in the electrical signal of the biosensor.
[0088] Since the description of the above biosensor is as described above, a detailed description is omitted.
[0089] The real-time nicotine analysis method in saliva using the above biosensor is characterized in that the detection limit of nicotine is 1 pM.
[0090] Hereinafter, preferred manufacturing examples and experimental examples are presented to aid in understanding the present invention. However, the following manufacturing examples and experimental examples are provided solely to aid in understanding the present invention, and the present invention is not limited to the following manufacturing examples and experimental examples.
[0091]
[0092] [Manufacturing Example 1: Manufacturing of an electrode including a nanovesicle structure containing CNT / ISM / TRPA1]
[0093] (1) Preparation of nanovesicles containing TRPA1
[0094] HEK-293T cells were cultured in DMEM medium (Dulbecco's Modified Eagle Medium) supplemented with 10% fetal bovine serum (FBS) and 100 μg / ml penicillin at 37°C and 5% CO2. The cells were seeded at 10 in a 100 mm dish. 6 Cells were seeded at a density of 10 cells / ml. Afterwards, TRPA1 was introduced into the cells using lipofectamine, and the cells were cultured for 48 hours.
[0095] Next, the cells were cultured in serum-free DMEM containing cytochalasin B (10 μg / ml) at 37°C for 30 minutes. Cytochalasin B is a type of mycotoxin that can permeate cell membranes and can reduce cell membrane stability by interfering with the formation of contractile microfilaments. The cell suspension was vigorously stirred for 30 seconds, and then TRPA1 nanovesicles were isolated from the cells through two-step centrifugation (500×g for 10 minutes and 15,000×g for 30 minutes).
[0096] The above nanovesicles were then redispersed in PBS containing a protease inhibitor cocktail and stored frozen at -80°C.
[0097]
[0098] (2) Preparation of calcium ion selective membrane solution
[0099] 1 g of a mixture of DOS (dioctylsebacate) as a plasticizer, PVC (polyvinyl chloride) as a matrix, Na-TFPB (sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate) as a lipophilic additive, and calcium ionophore II as an ion-selective substance (weight ratio of 65.45 / 33 / 0.55 / 1) was dissolved in 6.6 mL of tetrafuran to obtain calcium ions (Ca 2+ ) selective membrane solution was prepared. The calcium ion (Ca 2+ ) The selective membrane solution was stored at 4 °C.
[0100]
[0101] (3) Fabrication of electrodes formed with nanovesicle structures including CNT / ISM / TRPA1
[0102] As shown in Fig. 2, the working electrode, counter electrode, and reference electrode were printed with silver ink. Among them, a CNT film (10) was printed with CNT ink on the working electrode (1), and the calcium ions (Ca) prepared in (2) were printed thereon. 2+ ) A CNT(10) / ISM(20) membrane was prepared by drop-casting a selective membrane solution.
[0103] To confirm whether a calcium ion selective film was successfully formed on the CNT film, the untreated CNT film and the CNT / ISM film were subjected to elemental analysis using energy dispersive X-ray spectroscopy (EDX), and the results are shown in Fig. 4.
[0104] FIG. 4 shows energy dispersive X-ray spectroscopy (EDX) spectra and field emission-scanning electron microscopy (FE-SEM) images of a CNT film and a CNT / ISM film according to a comparative example and an embodiment of the present invention.
[0105] As shown in Fig. 4, Ca 2+The Cl content of the CNT surface (b) coated with the ion-selective membrane (ISM) was 32.09%, which was increased by that of the untreated CNT surface (2.47%) (a). The Cl appears to be a component from polyvinyl chloride (PVC), and since the polyvinyl chloride is the main component of the calcium ion-selective membrane (ISM), it is believed that Ca is incorporated into the CNT / ISM membrane. 2+ You can see that ISM is successfully attached.
[0106] Next, the TRPA1-containing nanovesicles (TRPA1-NV) manufactured in (1) above were attached onto the CNT / ISM membrane. Specifically, a poly-d-lysine (PDL) solution (0.1 mg / ml in PBS) was introduced onto the CNT / ISM membrane and left for 1 hour, and then the TRPA1-containing nanovesicles were dropped onto the poly-d-lysine layer to allow the poly-d-lysine layer (30) and the TRPA1 nanovesicles (40) to be attached by positive-negative charge interactions, thereby manufacturing an electrode in which a CNT (10) / ISM (20) / TRPA1-containing nanovesicle (40) structure was formed.
[0107]
[0108] [Manufacturing Example 2: Manufacturing of a biosensor comprising a nanovesicle structure containing CNT / ISM / TRPA1]
[0109] A biosensor was manufactured using a working electrode formed with a nanovesicle structure including CNT / ISM / TRPA1 manufactured in the above Manufacturing Example 1, a counter electrode screen-printed with CNT ink, and a reference electrode screen-printed with silver ink.
[0110]
[0111] [Comparative Example 1]
[0112] A biosensor was fabricated using a working electrode screen-printed with CNT ink, a counter electrode screen-printed with silver ink, and a reference electrode screen-printed with silver ink.
[0113]
[0114] [Comparative Example 2]
[0115] In Manufacturing Example 1, a biosensor was manufactured in the same manner as Manufacturing Example 1, except that the TRPA1-containing nanovesicles were incubated in PBS containing 5 μM HC-030031 for 10 minutes to manufacture nanovesicles in which the activity of TRPA1 was inhibited.
[0116]
[0117] [Experimental Example 1: Effect of a Calcium Ion-Selective Membrane on a CNT Membrane on the Detection of Cigarette Smoke Extract]
[0118] In order to determine the effect of a calcium ion selective membrane formed on a CNT membrane in a biosensor structure according to the present invention on the detection of cigarette smoke extract, the following experiment was conducted.
[0119] The untreated CNT membrane of Comparative Example 1 and the CNT / ISM membrane manufactured in Manufacturing Example 1 were attached to electrodes and placed in artificial saliva containing calcium ions (containing 10 mM KCl, 7.4 mM NaCl, 2 mM CaCl2, 6.4 mM Na2HPO4, 2.5 mM NaHCO3 at pH 7.4), and exposed to cigarette smoke (CSE) at a concentration of 1% for 1 minute to be absorbed. The change in open circuit voltage (OCV) was measured and is shown in Fig. 5.
[0120] FIG. 5 is a graph showing the change in open circuit voltage (OCV) over time when an electrode having a CNT film and a CNT / ISM film attached thereto according to a comparative example and an embodiment of the present invention is positioned in artificial saliva containing calcium ions and exposed to 1% concentration of cigarette smoke (CSE).
[0121] As shown in Fig. 5, the OCV of the electrode with the untreated CNT film attached was non-specifically changed by exposure to cigarette smoke (CSE). This is thought to be because various ionic species in cigarette smoke acted as a resistor, changing the surface potential of the CNT film, which causes a noise signal. However, the electrode with the calcium ion-selective membrane (ISM)-coated CNT film attached did not show a non-specific reaction to exposure to cigarette smoke (CSE), indicating that the calcium ion-selective membrane (ISM) on the CNT surface acts as a physical barrier to block the interference caused by various ionic species contained in cigarette smoke. At this time, since cigarette smoke does not contain calcium ions, no change in calcium ions occurred, and therefore no change in OCV occurred. This confirmed that coating the ion-selective membrane on the CNT film is essential for blocking noise signals.
[0122]
[0123] Additionally, Ca of the CNT / ISM film 2+ In order to determine the selectivity for changes in OCV, changes in OCV were measured while adding 2 mM MgCl2, 2 mM KCl, 2 mM NaCl, and 2 mM CaCl2 to artificial saliva, respectively, and the results are shown in Fig. 6.
[0124] FIG. 6 is a graph showing the change in open circuit voltage (OCV) when an electrode having a CNT film and a CNT / ISM film attached thereto according to a comparative example and an embodiment of the present invention is placed in artificial saliva containing calcium ions, and 2 mM MgCl2, 2 mM KCl, 2 mM NaCl, and 2 mM CaCl2 are added to the artificial saliva.
[0125] As shown in Fig. 6, Ca 2+ ISM coated CNT film Mg 2+ , K + , Na +It was confirmed that OCV selectively increases only in response to changes in added calcium ions without reacting to other cations such as calcium ions.
[0126] Therefore, the biosensor according to the present invention includes a structure in which a calcium ion selective film is formed on a CNT film, thereby enabling high sensitivity detection of a target that changes calcium ions without interference or noise from other elements.
[0127]
[0128] [Experimental Example 2: The Effect of TRPA1 Ion Channels on Cigarette Smoke Detection]
[0129] In order to determine the effect of TRPA1 ion channels in the nanovesicles formed in the outermost layer of the structure on cigarette smoke detection in a biosensor including a CNT / ISM / TRPA1-containing nanovesicle structure according to the present invention, the following experiment was performed.
[0130] Specifically, after mock-infection of HEK-293T cells with TRPA1 or empty vector, the cells were exposed to calcium ions (Ca 2+ ) After adding a sensitive fluorescent dye, a 1% tobacco smoke extract (CSE) solution, in which 1% tobacco smoke was absorbed in artificial saliva containing calcium ions, was applied, and a series of images were captured over time for 150 seconds to measure the change in fluorescence intensity, which is shown in Fig. 7. At this time, intracellular calcium ions (Ca 2+ ) As the inflow increased, the fluorescence intensity increased.
[0131] Figure 7 is a graph showing the change in fluorescence intensity of cells over time when a calcium ion-sensitive fluorescent dye was added to HEK-293T cells mock-infected with TRPA1 or an empty vector and a cigarette smoke extract (CSE) solution was applied.
[0132] As shown in Figure 7, in cells expressing the TRPA1 ion channel, the fluorescence intensity increased in a time-dependent manner over time when a cigarette smoke extract (CSE) solution was applied, and saturated at 120 seconds. This increase in fluorescence intensity is thought to be due to the TRPA1 ion channel influxing calcium ions into the cell in response to the cigarette smoke extract.
[0133] However, in cells mock-infected with the empty vector, i.e., cells lacking TRPA1, no fluorescence response occurred within the cells even when exposed to cigarette smoke extract.
[0134] From this, it was confirmed that the TRPA1 ion channel changes the calcium ion concentration by influxing calcium ions in response to cigarette smoke extract.
[0135]
[0136] Additionally, to determine whether TRPA1-containing nanovesicles isolated from the HEK-293T cells also react to cigarette smoke extract, the following experiment was performed.
[0137] Specifically, for the nanovesicles containing TRPA1 prepared in (1) of Manufacturing Example 1 and the nanovesicles isolated from HEK-293T cells mock-infected with an empty vector, a calcium ion-sensitive fluorescent dye was added, and a 3% tobacco smoke extract (CSE) solution in which 3% cigarette smoke was absorbed in artificial saliva containing calcium ions was applied, and a series of images were captured over time for 300 seconds to measure the change in fluorescence intensity, which is shown in Fig. 8. At this time, the calcium ions (Ca) in the nanovesicles 2+ ) As the inflow increased, the fluorescence intensity increased.
[0138] Figure 8 is a graph showing the change in fluorescence intensity of nanovesicles over time when a calcium ion-sensitive fluorescent dye is added to nanovesicles containing TRPA1 or nanovesicles isolated from HEK-293T cells mock-infected with an empty vector, and a cigarette smoke extract (CSE) solution is applied.
[0139] As shown in Fig. 8, in the case of TRPA1-containing nanovesicles containing the TRPA1 ion channel, even though they were isolated from cells, when a cigarette smoke extract (CSE) solution was applied, the fluorescence intensity increased over time, indicating that TRPA1-containing nanovesicles isolated from cells also responded to cigarette smoke extract at a similar level as cells to inflow calcium ions.
[0140] From this, it was confirmed that nanovesicles containing TRPA1 also change the calcium ion concentration by influxing calcium ions in response to cigarette smoke extract.
[0141]
[0142] [Experimental Example 3: Measurement of nicotine detection performance of a biosensor including a nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention]
[0143] Nicotine in cigarette smoke primarily activates TRPA1, which then translocates calcium ions into the cell membrane, altering calcium ion concentration. However, nicotine has a short half-life, being converted to metabolites after two hours. Therefore, rapid, real-time detection of even small amounts of nicotine in saliva is necessary to detect nicotine.
[0144] Accordingly, the following experiment was performed to measure the nicotine detection performance of a biosensor including a nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention.
[0145] Specifically, nicotine was added to artificial saliva containing 10 mM KCl, 7.4 mM NaCl, 2 mM CaCl2, 6.4 mM Na2HPO4, and 2.5 mM NaHCO3 at pH 7.4, and then dropped onto the biosensor manufactured in Manufacturing Example 1 to measure the change in open circuit voltage (OCV).
[0146] As a control group (CTL), a biosensor without TRPA1 of Comparative Example 1 was used, and as a control group, a biosensor with inhibited TRPA1 activity of Comparative Example 2 was used.
[0147] The measurement results are shown in Fig. 9.
[0148] FIG. 9 is a graph showing the detection performance of a biosensor including a nanovesicle structure including CNT / ISM / TRPA1 according to one embodiment of the present invention according to nicotine concentration.
[0149] As shown in Fig. 9, a biosensor including a nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention has a -12 Nicotine at a concentration of M (i.e., 1 pM) was detected by showing a change in OCV, and showed a linear change in OCV in proportion to the nicotine concentration, whereas in the control biosensor without TRPA1 channel and in the biosensor in which TRPA1 activity was blocked by a TRPA1 inhibitor (HC-030031), almost no change in OCV occurred even with an increase in nicotine concentration.
[0150] Therefore, a biosensor including a nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention can rapidly and quantitatively detect a minute concentration of nicotine in artificial saliva.
[0151]
[0152] [Experimental Example 4: Measurement of nicotine detection performance in actual saliva of a biosensor including a nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention]
[0153] In order to determine whether a biosensor including a nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention can measure the nicotine concentration in actual saliva in real time in an actual field, the following experiment was performed.
[0154] Specifically, as shown in Fig. 3, the actual saliva of a smoker was continuously dropped onto a biosensor including the nanovesicle structure including CNT / ISM / TRPA1 of Manufacturing Example 1 once every 10 seconds, and the OCV change was measured in real time, and is shown in Fig. 10.
[0155] FIG. 10 is a graph showing the detection performance of a biosensor including a nanovesicle structure including CNT / ISM / TRPA1 according to one embodiment of the present invention according to the concentration of nicotine in actual saliva.
[0156] As shown in Fig. 10, the biosensor including the nanovesicle structure containing CNT / ISM / TRPA1 according to the present invention shows a change in OCV within 10 seconds depending on the nicotine concentration in actual saliva, thereby enabling quantitative real-time detection of the nicotine concentration in actual saliva, confirming its usability in actual fields.
[0157]
[0158] The present invention is not limited to the above-described embodiments, but can be manufactured in a variety of different forms. Those skilled in the art will appreciate that the present invention can be implemented in other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.
[0159]
[0160] [Explanation of symbols]
[0161] 1: Working electrode
[0162] 2: Counter electrode
[0163] 3: Reference electrode
[0164] 10: Carbon nanotube (CNT) membrane
[0165] 20: Calcium ion-selective membrane
[0166] 30: Linker (poly-d-lysine (PDL))
[0167] 40: Nanovesicles containing TRPA1
Claims
1. Crystalline carbon film; A calcium ion selective film formed on the above crystalline carbon film; and Comprising nanovesicles containing TRPA1 (Transient receptor potential channel, subfamily A, member 1) formed on the calcium ion selective membrane, Structure for real-time nicotine detection biosensor.
2. In paragraph 1, A structure characterized in that the nanovesicles containing the TRPA1 are chemically bonded and immobilized on the calcium ion selective membrane.
3. In paragraph 2, The above chemical bond is a structure in which poly-D-lysine is fixed as a linker.
4. A real-time nicotine detection biosensor comprising the structure of paragraph 1.
5. In paragraph 4, The above real-time nicotine detection biosensor is a biosensor characterized in that it quantitatively detects the nicotine concentration in saliva.
6. In paragraph 4, The above real-time nicotine detection biosensor is a biosensor characterized in that it quantitatively detects the nicotine concentration by detecting a change in the concentration of calcium ions that occurs when nicotine in saliva selectively reacts with TRPA1 on a structure within the sensor and calcium ions in saliva flow into nanovesicles containing TRPA1.
7. In paragraph 4, The above real-time nicotine detection biosensor is a biosensor characterized in that the detection limit of nicotine is 1 pM.
8. A step of processing a saliva sample of the subject of measurement into the biosensor of paragraph 4; and A step of measuring an electrical signal of the biosensor; comprising; A method for real-time nicotine analysis in saliva.
9. In paragraph 8, A real-time nicotine analysis method in saliva, characterized in that the measurement of the above electrical signal is performed by measuring a change in open circuit voltage (OCV).
10. In paragraph 8, A real-time nicotine analysis method in saliva, characterized in that the above analysis method further includes a step of quantitatively analyzing the nicotine concentration according to the magnitude of change in the electrical signal of the biosensor.
11. In paragraph 8, The above analysis method is a real-time nicotine analysis method in saliva, characterized in that the detection limit of nicotine is 1 pM.
Citation Information
Patent Citations
Methods And Compositions For Modifying Sensorial Perception
US20150272907A1
Methods for Determining Modulators of Insect Transient Receptor Potential V (TRPV) Channel
US20170003279A1
KR20210118671A
